1. |
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68(6): 394-424.
|
2. |
van Dam PA, van Dam VC, Altintas S, et al. Neoadjuvant endocrine treatment in early breast cancer: an overlooked alternative? Eur J Surg Oncol, 2016, 42(3): 333-342.
|
3. |
Sánchez-Muñoz A, Plata-Fernández YM, Fernández M, et al. The role of immunohistochemistry in breast cancer patients treated with neoadjuvant chemotherapy: an old tool with an enduring prognostic value. Clin Breast Cancer, 2013, 13(2): 146-152.
|
4. |
Untch M, Fasching PA, Konecny GE, et al. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study Groups. J Clin Oncol, 2011, 29(25): 3351-3357.
|
5. |
von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol, 2012, 30(15): 1796-1804.
|
6. |
Ring A, Webb A, Ashley S, et al. Is surgery necessary after complete clinical remission following neoadjuvant chemotherapy for early breast cancer? J Clin Oncol, 2003, 21(24): 4540-4545.
|
7. |
Namura M, Tsunoda H, Yagata H, et al. Discrepancies between pathological tumor responses and estimations of complete response by magnetic resonance imaging after neoadjuvant chemotherapy differ by breast cancer subtype. Clin Breast Cancer, 2018, 18(2): 128-134.
|
8. |
Dialani V, Chadashvili T, Slanetz PJ. Role of imaging in neoadjuvant therapy for breast cancer. Ann Surg Oncol, 2015, 22(5): 1416-1424.
|
9. |
National Health Commission of the People’s Republic of China. Chinese guidelines for diagnosis and treatment of breast cancer 2018 (English version). Chin J Cancer Res, 2019, 31(2): 259-277.
|
10. |
Matsuda N, Kida K, Ohde S, et al. Change in sonographic brightness can predict pathological response of triple-negative breast cancer to neoadjuvant chemotherapy. Breast Cancer, 2018, 25(1): 43-49.
|
11. |
《乳腺癌雌、孕激素受体免疫组织化学检测指南》编写组. 乳腺癌雌、孕激素受体免疫组织化学检测指南. 中华病理学杂志, 2015, 44(4): 237-239.
|
12. |
江泽飞, 邵志敏, 徐兵河. 人表皮生长因子受体 2 阳性乳腺癌临床诊疗专家共识 2016. 中华医学杂志, 2016, 96(14): 1091-1096.
|
13. |
Shintia C, Endang H, Diani K. Assessment of pathological response to neoadjuvant chemotherapy in locally advanced breast cancer using the Miller-Payne system and TUNEL. Malays J Pathol, 2016, 38(1): 25-32.
|
14. |
Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis. Lancet, 2014, 384(9938): 164-172.
|
15. |
Fumagalli D, Bedard PL, Nahleh Z, et al. A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints. Lancet Oncol, 2012, 13(6): e240-e248.
|
16. |
Green MC, Buzdar AU, Smith T, et al. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol, 2005, 23(25): 5983-5992.
|
17. |
von Minckwitz G, Rezai M, Loibl S, et al. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase Ⅲ GeparQuattro study. J Clin Oncol, 2010, 28(12): 2015-2023.
|
18. |
Schaefgen B, Mati M, Sinn HP, et al. Can routine imaging after neoadjuvant chemotherapy in breast cancer predict pathologic complete response? Ann Surg Oncol, 2016, 23(3): 789-795.
|
19. |
De Los Santos JF, Cantor A, Amos KD, et al. Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium Trial 017. Cancer, 2013, 119(10): 1776-1783.
|
20. |
Chen JH, Feig B, Agrawal G, et al. MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy. Cancer, 2008, 112(1): 17-26.
|
21. |
Yuan Y, Chen XS, Liu SY, et al. Accuracy of MRI in prediction of pathologic complete remission in breast cancer after preoperative therapy: a meta-analysis. AJR Am J Roentgenol, 2010, 195(1): 260-268.
|
22. |
Marinovich ML, Houssami N, Macaskill P, et al. Meta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapy. J Natl Cancer Inst, 2013, 105(5): 321-333.
|
23. |
Marinovich ML, Houssami N, Macaskill P, et al. Accuracy of ultrasound for predicting pathologic response during neoadjuvant therapy for breast cancer. Int J Cancer, 2015, 136(11): 2730-2737.
|
24. |
Vriens BE, de Vries B, Lobbes MB, et al. Ultrasound is at least as good as magnetic resonance imaging in predicting tumour size post-neoadjuvant chemotherapy in breast cancer. Eur J Cancer, 2016, 52: 67-76.
|
25. |
Spick C, Baltzer PA. Diagnostic utility of second-look US for breast lesions identified at MR imaging: systematic review and meta-analysis. Radiology, 2014, 273(2): 401-409.
|
26. |
Rosen EL, Blackwell KL, Baker JA, et al. Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy. AJR Am J Roentgenol, 2003, 181(5): 1275-1282.
|
27. |
Ballesio L, Gigli S, Di Pastena F, et al. Magnetic resonance imaging tumor regression shrinkage patterns after neoadjuvant chemotherapy in patients with locally advanced breast cancer: Correlation with tumor biological subtypes and pathological response after therapy. Tumour Biol, 2017, 39(3): 1010428317694540.
|
28. |
Matsuda N, Hayashi N, Ohde S, et al. A nomogram for predicting locoregional recurrence in primary breast cancer patients who received breast-conserving surgery after neoadjuvant chemotherapy. J Surg Oncol, 2014, 109(8): 764-769.
|
29. |
Kim TH, Kang DK, Yim H, et al. Magnetic resonance imaging patterns of tumor regression after neoadjuvant chemotherapy in breast cancer patients: correlation with pathological response grading system based on tumor cellularity. J Comput Assist Tomogr, 2012, 36(2): 200-206.
|
30. |
Chen JH, Bahri S, Mehta RS, et al. Impact of factors affecting the residual tumor size diagnosed by MRI following neoadjuvant chemotherapy in comparison to pathology. J Surg Oncol, 2014, 109(2): 158-167.
|
31. |
Fukuda T, Horii R, Gomi N. Accuracy of magnetic resonance imaging for predicting pathological complete response of breast cancer after neoadjuvant chemotherapy: association with breast cancer subtype. Springerplus, 2016, 5: 152.
|
32. |
Zhang X, Wang D, Liu Z, et al. The diagnostic accuracy of magnetic resonance imaging in predicting pathologic complete response after neoadjuvant chemotherapy in patients with different molecular subtypes of breast cancer. Quant Imaging Med Surg, 2020, 10(1): 197-210.
|
33. |
Esserman LJ, Berry DA, DeMichele A, et al. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL–CALGB 150007/150012, ACRIN 6657. J Clin Oncol, 2012, 30(26): 3242-3249.
|
34. |
Arnould L, Arveux P, Couturier J, et al. Pathologic complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER-2 amplification. Clin Cancer Res, 2007, 13(21): 6404-6409.
|
35. |
Lee HJ, Kim JY, Park SY, et al. Clinicopathologic significance of the intratumoral heterogeneity of HER2 gene amplification in Her2-positive breast cancer patients treated with adjuvant trastuzumab. Am J Clin Pathol, 2015, 144(4): 570-578.
|